Relevant bibliographies by topics / Pharmaceutical industry Australia

Academic literature on the topic 'Pharmaceutical industry Australia'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical industry Australia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical industry Australia"

1

Rae, Ian D. "Vitamin A and Australian Fish Liver Oils." Historical Records of Australian Science 25, no. 1 (2014): 55. http://dx.doi.org/10.1071/hr14005.

Full text
Abstract:
Research by an organic chemist at the University of Melbourne and support from Australia's Council for Scientific and Industrial Research provided the basis for a wartime industry when Australia was unable to maintain access to traditional supplies of cod liver oil from Britain and Norway in the 1940s. Two major pharmaceutical companies gathered oil from the livers of sharks in southern Australia that was rich in vitamin A, and so met domestic and military needs for this nutritional supplement. Other companies joined in and by the end of the war Australia had a flourishing industry that derived synergy from the marketing of shark flesh for human consumption. South Africa was a leader among countries that expanded fish-oil production in the late 1940s, as a result of which Australian producers suffered from import competition. A Tariff Board hearing found that the Australian industry was unable to meet local needs and so did not recommend increased tariffs. The industry struggled for years until the perceived nutritional benefits of other components of the fish oils helped to revive markets.
APA, Harvard, Vancouver, ISO, and other styles
2

Fabbri, Alice, Swestika Swandari, Edith Lau, Agnes Vitry, and Barbara Mintzes. "Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis." International Journal of Health Services 49, no. 2 (January 15, 2019): 273–93. http://dx.doi.org/10.1177/0020731418823376.

Full text
Abstract:
Relationships between consumer organizations and pharmaceutical manufacturers are the focus of transparency efforts in some jurisdictions, including Australia. This study describes the frequency and nature of industry sponsorship of Australian health consumer organizations and examines the link between sponsorship of the most highly funded organizations and manufacturers’ requests for public reimbursement of products for related health conditions. We downloaded 130 transparency reports covering the period January 2013 to December 2016 from the website of Medicines Australia and carried out a descriptive analysis. For the most heavily funded organizations and their sponsors, we examined Public Summary Documents of the Pharmaceutical Benefits Advisory Committee to identify relevant products under consideration for public reimbursement over the study period. Thirty-four pharmaceutical companies provided 1,482 sponsorships to 230 organizations, spending a total of AU$34,507,810. The top clinical areas in terms of amount of funding received were cancer, eye health, and nervous system disorders. The sponsors of the most highly funded groups were companies that in most cases had drugs under review for public reimbursement for conditions covered by these organizations. Interactions between the pharmaceutical industry and consumer organizations are common and require careful management to prevent biases that may favor sponsors’ interests above those of patients and the public.
APA, Harvard, Vancouver, ISO, and other styles
3

Parker, Lisa, Emily A. Karanges, and Lisa Bero. "Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study." BMJ Open 9, no. 2 (February 2019): e024928. http://dx.doi.org/10.1136/bmjopen-2018-024928.

Full text
Abstract:
ObjectivesTo describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine the impact of the 2015 changes to Australia’s self-regulated system of transparency.DesignObservational database study.SettingAustralia.ParticipantsPublicly available reports submitted by members of Australian pharmaceutical industry trade organisations, Medicines Australia and the Generic and Biosimilar Medicines Association (GBMA) (October 2011–December 2017).ExposureChanges to transparency reporting requirements with the updates of pharmaceutical industry Codes of Conduct in 2015.Main outcome measuresElements of healthcare sector spending that members of industry organisations are required to publicly disclose; cumulative amount of disclosed spending (monthly average) in the year prior to and following the revision.ResultsThere was a 34.1% reduction in disclosed spending from Medicines Australia member companies in the year after the 2015 changes to the Code of Conduct were introduced ($A89 658 566 in the preceding year, October 2014–September 2015; $A59 052 551 in the following year). The new Code allowed for reduced reporting of spending on food and beverages at events and for sponsored healthcare professionals. However, there was enhanced transparency around identification of individual health professionals receiving payments. GBMA member reporting totalled $A2 580 402 in the year prior to the revision, then ceased.ConclusionsThis study shows the limitations of a self-regulatory system around industry disclosure of spending. We advocate for robust regulatory systems, such as legislation, to promote mandatory long-lasting public transparency.
APA, Harvard, Vancouver, ISO, and other styles
4

Lau, Edith, Alice Fabbri, and Barbara Mintzes. "How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study." Australian Health Review 43, no. 4 (2019): 474. http://dx.doi.org/10.1071/ah17288.

Full text
Abstract:
Objective The aim of this study was to investigate how health consumer organisations manage their relationships with the pharmaceutical industry in Australia. Methods We identified 230 health consumer organisations that received pharmaceutical industry support from 2013 to 2016 according to reports published by Medicines Australia, the industry trade association. A random sample of 133 organisations was selected and their websites assessed for financial transparency, policies governing corporate sponsorship and evidence of potential industry influence. Results In all, 130 of the 133 organisations evaluated received industry funding. Of these 130, 68 (52.3%; 95% confidence interval (CI) 43.4–61.1%) disclosed this funding. Nearly all (67; 98.5%) reported the identity of their industry donors, followed by uses (52.9%), amount (13.2%) and proportion of income from industry (4.4%). Less than one-fifth (24/133; 18.0%; 95% CI 11.9–25.6%) had publicly available policies on corporate sponsorship. Six organisations (7.2%; 95% CI 2.7–15.1%) had board members that were currently or previously employed by pharmaceutical companies, and 49 (36.8%; 95% CI 28.6–45.6%) had company logos, web links or advertisements on their websites. Conclusion Industry-funded health consumer organisations in Australia have low transparency when reporting industry funding and few have policies governing corporate sponsorship. Relationships between health consumer organisations and the industry require effective actions to minimise the risks of undue influence. What is known about this topic? Pharmaceutical industry funding of health consumer organisations is common in the US and Europe, yet only a minority of such organisations publicly disclose this funding and have policies regulating their relationships with industry. What does this paper add? Industry-funded health consumer organisations in Australia have inadequate financial transparency and rarely have policies addressing corporate funding. Organisations that have received more industry funding are more likely to report it publicly. What are the implications for practitioners? Robust policies addressing corporate sponsorship and increased transparency are needed to maintain the independence of health consumer organisations. Governments may also consider regulating non-profit organisations to ensure public reporting of funding sources.
APA, Harvard, Vancouver, ISO, and other styles
5

Condon, Wayne, and Justin Lambert. "The vexed issue of therapeutic combinations and contributory patent infringement in Australia." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 9, no. 4 (December 2012): 207–13. http://dx.doi.org/10.1177/1741134312469806.

Full text
Abstract:
The Australian Patents Act includes a provision which deems the supplier of a product to a person who will use that product in a manner which infringes a patent to infringe that patent as a contributory infringer. The concept of contributory patent infringement is one known to the patent laws of many countries, but in many respects the way in which Australian Courts have approached contributory patent infringement gives far greater scope to a patentee than in many of those jurisdictions. The consequence for the generic pharmaceutical industry in Australia is potentially far-reaching. This article looks at the practical consequences of some recent Australian Federal Court decisions which have been decided in the area and which create practical hurdles that any generic entrant into the Australian marketplace will need to navigate.
APA, Harvard, Vancouver, ISO, and other styles
6

Hirst, Christine A. "GOVERNMENT INITIATIVES IN THE DEVELOPMENT OF A PHARMACEUTICAL INDUSTRY IN AUSTRALIA." Clinical and Experimental Pharmacology and Physiology 19, no. 1 (January 1992): 57–61. http://dx.doi.org/10.1111/j.1440-1681.1992.tb00398.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Karanges, Emily Aspasia, Conrad Nangla, Lisa Parker, Alice Fabbri, Cynthia Farquhar, and Lisa Bero. "Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study." BMJ Open 11, no. 9 (August 31, 2021): e049710. http://dx.doi.org/10.1136/bmjopen-2021-049710.

Full text
Abstract:
ObjectivesTo investigate the extent and nature of pharmaceutical industry payments related to fertility and assisted reproduction in Australia.Design and settingThis retrospective observational study employed four databases compiled from publicly available pharmaceutical industry transparency reports on educational event sponsorship (October 2011–April 2018), payments to healthcare professionals (October 2015–April 2018) and patient group support (January 2013–December 2017). Analyses were restricted to fertility-related payments by two major manufacturers of fertility medicines in Australia: Merck Serono and Merck, Sharp and Dohme (MSD).Primary and secondary outcome measuresDescriptive statistics on fertility-related payments and other transfers of value (counts, total and median costs in Australian dollars) for educational events and to healthcare professionals and patient groups.ResultsBetween October 2011 and April 2018, Merck Serono and MSD spent $A4 522 263 on 970 fertility-related events for healthcare professionals, including doctors, nurses and fertility scientists. 56.8% (551/970) events were held by fertility clinics and 29.3% (284/970) by professional medical associations. Between October 2015 and April 2018, Merck Serono spent $A403 800 across 177 payments to 118 fertility healthcare professionals, predominantly for educational event attendance. Recipients included obstetricians and gynaecologists (76.3% of payments, 135/177), nurses (11.3%, 20/177) and embryologists/fertility scientists (9.6%, 17/117). The highest paid healthcare professionals held leadership positions in major fertility clinics. Merck Serono provided $A662 850 to fertility-related patient groups for advocacy and education (January 2013–December 2017).ConclusionsThe pharmaceutical industry sponsored a broad range of fertility clinicians and organisations, including doctors, nurses, embryologists, professional medical organisations, fertility clinics and patient groups. This sponsorship may contribute to the overuse of fertility services.
APA, Harvard, Vancouver, ISO, and other styles
8

Qureshi, Athar Mahmood Ahmed, and Nina Evans. "Deterrents to knowledge-sharing in the pharmaceutical industry: a case study." Journal of Knowledge Management 19, no. 2 (April 7, 2015): 296–314. http://dx.doi.org/10.1108/jkm-09-2014-0391.

Full text
Abstract:
Purpose – This study aims to explore deterrents to knowledge-sharing in pharmaceutical manufacturing. Effective knowledge-sharing is fundamental to stimulation of the process of knowledge absorption. The limited proximal communication between the employees in the pharmaceutical industry stifles their knowledge-sharing behaviour significantly. Design/methodology/approach – A cross-sectional case study, consisting of semi-structured interviews with managers and scientists, was conducted in a multinational pharmaceutical company in Australia. Respondents were asked to answer questions regarding their current knowledge-sharing practices and to identify organisational deterrents to knowledge-sharing. The data were condensed into themes according to the thematic analysis method. Findings – The pharmaceutical industry is extensively regulated and its excessive competitiveness is cultivating organisational reticence towards the development of a knowledge-sharing culture. Nine categories of deterrents to intra- (within) and inter-organisational (between organisations) knowledge-sharing have been identified. These categories include high cost of sharing knowledge, information technology limitations, knowledge-hiding, lack of socialisation, lack of trust culture, non-educational mindset, organisational politics, poor leadership and time pressure. Research limitations/implications – The population of this study consists of managers and practitioners working for a pharmaceutical company. Hence, the generalisability of the findings to other health-care settings is unknown. Practical implications – The findings have implications for leaders and managers who should be aware of these professional diversities, instigators as well as the ripple effects of limited knowledge-sharing to guide the organisation towards developing an optimal knowledge-sharing culture. Originality/value – A focussed investigation of knowledge-sharing behaviour within the pharmaceutical industry in Australia, considering the pressure applied to this industry over the past decade. This case study specifically focusses on the diversity of deterrents to knowledge-sharing in the pharmaceutical manufacturing industry.
APA, Harvard, Vancouver, ISO, and other styles
9

Kerridge, Ian. "Comment: Interactions Between the Medical Profession and the Pharmaceutical Industry in Australia." Australasian Psychiatry 16, no. 3 (January 2008): 166–68. http://dx.doi.org/10.1080/10398560802005092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Harvey, Roy. "And on the cover of the Guide were two words in red - Don't Panic." Australian Health Review 24, no. 2 (2001): 15. http://dx.doi.org/10.1071/ah010015.

Full text
Abstract:
Roy Harvey is a consultant in health financing, works both in Australia and in developing countries and hasundertaken research and analysis on the economics of the pharmaceutical industry and the PBS since 1968.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical industry Australia"

1

Beyer, Lorraine R. "Heroin importation and higher level drug dealing in Australia : opportunistic entrepreneurialism /." Connect to thesis, 2005. http://eprints.unimelb.edu.au/archive/00001612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." full-text, 2008. http://eprints.vu.edu.au/1960/1/sweeny.pdf.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." Thesis, full-text, 2008. https://vuir.vu.edu.au/1960/.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
4

Lofgren, Hans. "Globalisation of the pharmaceutical industry and the Australian state : the transformation of a policy network /." Connect to thesis, 1997. http://eprints.unimelb.edu.au/archive/00000300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Searles, Andrew. "A preliminary analysis of the pharmaceutical provisions in the Australia-United States Free Trade Agreement on prescription medicines in Australia." Thesis, 2010. http://hdl.handle.net/1959.13/44658.

Full text
Abstract:
Research Doctorate - Doctor of Philosophy (PhD)
In January 2005 Australia implemented the Australia-United States Free Trade Agreement (AUSFTA). The AUSFTA was a historic document because it laid out a closer trading association between Australia and its close ally, the United States (US). The Agreement was generally welcomed in both countries but it contained provisions that were controversial, perhaps none more so than those covering pharmaceuticals. In Australia there was deep concern over the effects of these provisions on the Pharmaceutical Benefits Scheme (PBS). A Senate Committee investigating the likely impact of the AUSFTA was apprehensive that the provisions would result in the PBS paying higher prices for some medicines. The many outcomes from the research reported in this thesis are preliminary but amongst them, three stood out. First, the AUSFTA instituted a number of small but significant changes to Australian pharmaceutical policies and processes. Some changes, around transparency and listing times, were positive while others, such as sponsor hearings before the PBAC, will probably have limited negative impact. Second, there is now a need to consider the AUSFTA commitments when Australian health policy is reassessed in the future, which will now make Australia’s regulatory processes more complex. Third, it is argued that the AUSFTA may have had input into major reforms of the Australian PBS. These reforms delivered on an outcome that had been sought by the US: a weakening of reference pricing as used by the Australian PBS. The benefit from the change to reference pricing for Australia is unclear, but the PBS is now more vulnerable to higher prices for new medicines in the future.
APA, Harvard, Vancouver, ISO, and other styles
6

Searles, Andrew. "A preliminary analysis of the pharmaceutical provisions in the Australia-United States Free Trade Agreement on prescription medicines in Australia." 2010. http://hdl.handle.net/1959.13/44658.

Full text
Abstract:
Research Doctorate - Doctor of Philosophy (PhD)
In January 2005 Australia implemented the Australia-United States Free Trade Agreement (AUSFTA). The AUSFTA was a historic document because it laid out a closer trading association between Australia and its close ally, the United States (US). The Agreement was generally welcomed in both countries but it contained provisions that were controversial, perhaps none more so than those covering pharmaceuticals. In Australia there was deep concern over the effects of these provisions on the Pharmaceutical Benefits Scheme (PBS). A Senate Committee investigating the likely impact of the AUSFTA was apprehensive that the provisions would result in the PBS paying higher prices for some medicines. The many outcomes from the research reported in this thesis are preliminary but amongst them, three stood out. First, the AUSFTA instituted a number of small but significant changes to Australian pharmaceutical policies and processes. Some changes, around transparency and listing times, were positive while others, such as sponsor hearings before the PBAC, will probably have limited negative impact. Second, there is now a need to consider the AUSFTA commitments when Australian health policy is reassessed in the future, which will now make Australia’s regulatory processes more complex. Third, it is argued that the AUSFTA may have had input into major reforms of the Australian PBS. These reforms delivered on an outcome that had been sought by the US: a weakening of reference pricing as used by the Australian PBS. The benefit from the change to reference pricing for Australia is unclear, but the PBS is now more vulnerable to higher prices for new medicines in the future.
APA, Harvard, Vancouver, ISO, and other styles
7

Holmes, Anne Elizabeth. "Institutional change, the division of labour among firms and the Australian pharmaceuticals industry." Phd thesis, 2006. http://hdl.handle.net/1885/149619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Neville, Warwick John. "Healing the nation : access to medicines under the Pharmaceutical Benefits Scheme - the jurisprudence from history." Phd thesis, 2007. http://hdl.handle.net/1885/150188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ziaee, Maryam. "Big Data Analytics Adoption in Pharmaceutical Supply Chain Management and its Impact on SCOR Processes: A Qualitative Study of the Australian Pharmaceutical Industry." Thesis, 2019. https://vuir.vu.edu.au/41812/.

Full text
Abstract:
Big Data Analytics (BDA) in supply chain management has recently drawn the attention of academics and practitioners. Big data refers to a massive amount of data from different sources, in different formats, generated at high speed through voluminous of transactions in business environments as well as within supply chain networks. Traditional statistical tools and techniques find it difficult to analyse this massive data. Modern applications, in the form of BDA, assist organisations to capture, store, and analyse data specifically in the field of supply chain. Although there is an increasing trend among academics to investigate the potentials of BDA in supply chain, there is a paucity of research on BDA in the pharmaceutical supply chain context. In this research, the Australian pharmaceutical supply chain was selected as the case study. This industry is highly significant since the right medicine must reach the right patients, at the right time, in right quantity, in good condition, and at the right price to save lives. However, drug shortages remain a substantial problem for hospitals across Australia with implications on patient care, staff resourcing, and expenditure. Furthermore, a massive volume and variety of data is generated at fast speed from multiple sources (inter-organisational and intra-organisational data) in pharmaceutical supply chain, which needs to be captured and analysed to benefit operational decisions at every stage of supply chain processes. As the pharmaceutical industry lags behind other industries in using BDA, it raises the question of whether the adoption of BDA can improve transparency among pharmaceutical supply chain by enabling the partners to make informed decisions across their operational activities. This study, therefore, aims to explore the determinants of BDA adoption in Australian pharmaceutical supply chain. It also examines the potential impacts of BDA adoption in various processes using the Supply Chain Operations Reference model (SCOR model: plan, source, make, deliver, and return). The current study draws upon the Technology-Organisation-Environment (TOE) framework which is the most commonly used research framework that underpins the technology adoption studies. An exploratory qualitative approach was adopted to analyse data collected through interviews. Twenty semi-structured interviews with top managers in 15 organisations comprising of five pharmaceutical manufacturers, five wholesalers/distributors, and five public hospital pharmacies were undertaken to investigate their views on BDA adoption. Therefore, the supply chain is considered as the unit of analysis in this study. The interviews were transcribed and imported into NVivo software for thematic and cross-case analysis. The thematic results identified several technological, organisational, and environmental factors that could motivate the Australian pharmaceutical supply chain entities to adopt BDA. The findings revealed that BDA would be more practical and helpful in the planning process, followed by delivery and return. However, no significant benefits of BDA were perceived for the sourcing and making processes of medicines. This study contributes to the theory and practice. As business-related data gains momentum in business intelligence, this research explores the BDA potential in improving the supply chain processes of the pharmaceutical supply chain rather than focusing only on a single entity. Some earlier studies demonstrate BDA adoption in context of clinical healthcare; however, this study is the first of its kind that explores the determinants and benefits of BDA adoption in the Australian pharmaceutical supply chain comprising of hospital pharmacies, wholesalers/distributors, and manufacturers. Furthermore, this study also offers practical and managerial implications by providing top managers with a picture of the technological, organisational and environmental factors that may influence their BDA adoption decision. Moreover, this research enhances managers’ insight into the potentials of BDA at every stage of supply chain processes such as plan, source, make, deliver, and return and helps to improve decision-making in their supply chain operations. The findings will turn the rhetoric of data-driven decision into a reality where the managers may opt for analytics for improved decision-making in the supply chain processes.
APA, Harvard, Vancouver, ISO, and other styles
10

Chuankamnerdkarn, Prasit. "Patterns and determinants of Australia's international trade in pharmaceuticals." Thesis, 1997. https://vuir.vu.edu.au/16072/.

Full text
Abstract:
This thesis reports the results of a comprehensive analysis of the patterns and determinants of Australia's international trade in pharmaceuticals during the period 1975 to 1992. The thesis provides a thorough review of the theories, measurements and determinants of international trade. Thus, the thesis synthesises the theoretical framework and econometric methodology for analysing international trade patterns and their determinants. This synthesis will be beneficial to those wishing to undertake research in the area of international trade.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical industry Australia"

1

Parry, Thomas G. The Australian pharmaceutical industry: Achievements, prospects, and the policy environment. North Sydney, NSW: Australian Pharmaceutical Manufacturers Association, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Montagnana-Wallace, Neil. Healthy past, beautiful future: Celebrating 100 years of Australian Pharmaceutical Industries. Thornbury, Vic: Bounce Books, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pharmscience. The Australian contract manufacturing resource guide for the pharmaceutical and veterinary industries. 2nd ed. Caulfield East, Vic: Julex Pty Ltd, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Johnston, M. The Australian pharmaceutical subsidy gambit: Transmuting deadweight loss and oligopoly rents to consumer surplus. Cambridge, MA: National Bureau of Economic Research, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

IBP, USA. Australia Medical and Pharmaceutical Industry Handbook. International Business Publications, USA, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schweitzer, Stuart O., and Z. John Lu. The Global Pharmaceutical Industry. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190623784.003.0005.

Full text
Abstract:
This chapter examines the supply of pharmaceuticals worldwide, including production and sales, R&D, traditional medicines, and international trade. Worldwide consolidation of drug manufacturers, a trend dating back to the early 1990s, will also be examined. The discussion focuses on the unique characteristics of the industry in several key regions and countries, including the Europe Union, China, Japan, India, and Brazil. This chapter also looks at the impact of government price control on pharmaceutical R&D in Canada and Australia. Issues regarding access to innovative medicines in developing nations, including possible causes and recommended solutions, are covered at the end of chapter.
APA, Harvard, Vancouver, ISO, and other styles
7

Pharmaceutical Industry in Australia: A Strategic Entry Report, 2000. Icon Group International, Inc., 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gilling, Tom, and Clive Small. Bad Company. Allen & Unwin, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ibp, Inc. Australia Medical, Pharmaceutical Industry Handbook Volume 1 Strategic Information, Regulations Contacts. Lulu Press, Inc., 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Biomedical, biotechnology, and pharmaceutical innovation: Australia's opportunities. Double Bay, N.S.W: CL Creations, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical industry Australia"

1

Epp, Joanne, Bonny Parkinson, and Sally Hawse. "Health System Sustainability: The Pharmaceutical Benefits Scheme in Australia." In Industry and Higher Education, 13–44. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0874-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lin, Chad, and Geoffrey Jalleh. "Evaluation of B2B Pharmaceutical Supply Chain in Australia." In Advances in E-Business Research, 56–79. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8133-0.ch003.

Full text
Abstract:
The pharmaceutical industry is one of the most innovative and research-intensive industries in the world. For example, five out of the top global Research and Development (R&D) companies were pharmaceutical companies. However, the industry is lagging behind other industries in adopting Business-to-Business (B2B) and supply chain technologies. With supply chain costs constituting around 25-40% of an organization's operating expenses, it is imperative for senior pharmaceutical executives to minimize this cost. Hence, the main objective of this chapter is to identify key B2B e-commerce management, evaluation, and benefits realization factors and challenges within the Australian pharmaceutical supply chain. The results of this study suggest that pharmaceutical companies not only need to carefully examine their B2B investment management and evaluation practices but also must invest in using appropriate evaluation methodologies for identifying and managing benefits, risks, and costs associated with their investments in B2B and supply chains.
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, Chad, and Geoffrey Jalleh. "Key Issues and Challenges for Managing and Evaluating B2B E-Commerce Projects within the Australian Pharmaceutical Supply Chain." In Pharmacoinformatics and Drug Discovery Technologies, 54–71. IGI Global, 2012. http://dx.doi.org/10.4018/978-1-4666-0309-7.ch005.

Full text
Abstract:
The use of Business-to-Business (B2B) e-commerce within the Australian pharmaceutical supply chain can potentially assist in setting up an infrastructure which supports complex, multiparty Internet-based trading and transactions among pharmaceutical manufacturers, wholesalers, hospitals, pharmacies, medical supply importers and exporters, and other players in the healthcare system. Effective use of B2B e-commerce can help these organizations reduce costs in supplying and distributing medicines and other medical-related products to the general public. However, despite high expectations for realizing the benefits of B2B e-commerce in the pharmaceutical supply chain, issues surrounding its evaluation and management remain poorly understood and relatively under-researched. This chapter presents case study findings on key management and evaluation issues and challenges in adopting and utilizing B2B e-commerce systems on eight pharmaceutical organizations in Australia. The key objectives of this study are: (1) to establish current practices and norms in evaluating B2B e-commerce investments and projects in the pharmaceutical industry; and (2) to identify key B2B e-commerce management issues and challenges within the Australian pharmaceutical supply chain. A key contribution of this chapter is the identification and examination of key issues and challenges faced by the pharmaceutical organizations undertaking B2B e-commerce activities within their supply chain. The findings will guide senior executives in these organizations to develop their own approaches or strategies to manage the opportunities and threats that exist in the Australian pharmaceutical supply chain.
APA, Harvard, Vancouver, ISO, and other styles
4

Okasha, Ahmad A., and Eman Zabalawi. "Medical, Pharmaceutical, and Healthcare Trade Relationships Between Australia and South Asian Nations." In Strategic Cooperation and Partnerships Between Australia and South Asia, 199–218. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-8657-0.ch009.

Full text
Abstract:
The global coronavirus (COVID-19) pandemic shocked the whole world. It had a disastrous impact on the economies and the healthcare systems of South Asian countries. Australia was able to minimize the COVID-19 impact by imposing a strict lockdown. The healthcare system and the healthcare industry in Australia are advanced and provide high quality pharmaceutical products and healthcare services. Australia has a lot to offer to South Asian countries in public health programs, quality of healthcare, complementary medicine products, clinical data management and development, and drug developments. Healthcare systems in South Asian countries vary significantly. Australia can play a significant role in developing the healthcare systems of South Asia. For instance, Australia can provide the traditional medicine sectors in South Asian countries with scientifically effective complementary medicines. Improving healthcare bilateral investment and the trade relationship between South Asia countries and Australia is a win/win partnership for SAARC nations post pandemic.
APA, Harvard, Vancouver, ISO, and other styles
5

Wijeratne, Tissa, Essie Low, and Christopher Neil. "Physician autonomy and the pharmaceutical industry." In Advocacy in Neurology, edited by Wolfgang Grisold, Walter Struhal, and Thomas Grisold, 53–60. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198796039.003.0005.

Full text
Abstract:
The physician–industry relationship is a topic that generates keen interest among physicians globally. This chapter reviews the potential risks and benefits of such relationships in patient care. Physicians must adhere to strict professional standards and strong ethical principles, with the prime interest of offering the best possible care for the patient while using the resources available through pharmaceutical industry partnerships. One must never cross the boundaries in this complex interaction; physicians should continue to be the best advocates for patients, and not the pharmaceutical industry. Other aspects of relationships between the pharmaceutical industry and doctors’, trainees’, and residents’ perspectives in the industry, essential drug policy solutions in Sri Lanka, and several key points from the Australian Medical Association’s position statement on medical practitioner’s relationships with industries, are also discussed.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical industry Australia"

1

Karanges, Emily, Natasha Ting, Lisa Parker, Alice Fabbri, and Lisa Bero. "19 Pharmaceutical industry payments to thought leaders in cardiovascular disease and diabetes." In Preventing Overdiagnosis Abstracts, December 2019, Sydney, Australia. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-pod.33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical industry Australia' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography